Top Washington DC, Biotech Companies (43)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products
We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies.
For 60 years, HHMI has been moving science forward. We’re an independent, ever-evolving philanthropy that supports basic biomedical scientists and science educators with the potential for transformative impact. We invest in people, not projects. We encourage collaborative and results-driven working styles and offer an adaptable environment where employees can function at their highest level. As HHMI scientists continue to push boundaries in laboratories and classrooms, you can be sure that your contributions while working at HHMI are making a difference. To move science forward, we need experts in areas such as communications, finance, human resources, information technology, investments, and law as well as scientists. Visit our website at http://www.hhmi.org
Precision is the first global precision medicine clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.
Official account of the National Center for Biotechnology Information (NCBI) at the National Library of Medicine. NCBI serves as an international resource for the scientific research community - providing access to public databases and software tools for analyzing biological data, as well as performing research in computational biology. The NCBI was established in 1988 by an act of the United States Congress as division of the National Library of Medicine at the National Institutes of Health, with a mission to find new approaches to deal with the increasing volume and complexity of biological data in order to facilitate the understanding of genes and their role in health and disease. The NCBI is made up of multidisciplinary research and development teams composed of molecular biologists, biochemists, structural biologists, clinicians, mathematicians, and computer scientists who: Archive: Gather scientific and medical research data from around the globe • Serve as the largest repository of the world’s primary biological research data • Produce curated datasets to enhance the value and usability of the primary data Access: Develop systems for discovering and integrating scientific and medical data • Create search tools and data cross-referencing mechanisms • Display and enable download of information from the world's largest collection of biological data Advance: Promote understanding of processes that effect health and disease • Perform cutting-edge research in computational biology • Design and build algorithms, programs and systems for analysis of biological data • Provide support and training through a varied and vigorous outreach program
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
FierceMedicalDevices provides breaking news and critical insights into the medical device and diagnostics industries.
GeneCopoeia, Inc. is a leading provider and manufacture of genomics and proteomics products and services worldwide. GeneCopoeia has developed a series of cutting edge research tools, including the largest collection of expression-ready clones (ORF cDNA, Promoter, shRNA, miRNA), comprehensive genome-editing tools (CRISPR and TALEN), as well as highly efficient viral delivery systems (Lentivirus and AAV). In addition to its genomics and proteomics products, GeneCopoeia also offers fluorescent detection reagents (e.g. non-toxic DNA gel stains, protein gel stains, cell biology assay kits, labeling dyes and antibodies), as well as other molecular biology reagents and kits (e.g. luciferase assay kits, qPCR arrays and products, transfection reagents and more).
Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has been widely adopted by researchers in pharmaceutical companies, government institutions, universities, and clinical laboratories worldwide for its high sensitivity, excellent reproducibility, and wide dynamic range. Throughout its history, MSD has continued to evolve its technology platform to enable researchers to solve complex biological questions and, as the Company looks toward the future, it is expanding into clinical applications and the emerging fields of personalized medicine and companion diagnostics.
NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology. NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities. For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond.
Founded in 1967, Riverside Research is a not-for-profit organization chartered to advance scientific research for the benefit of the US government and in the public interest. Through our open innovation concept, we invest in multi-disciplinary research and development and encourage collaboration to accelerate innovation and advance science. Riverside Research conducts independent research in machine learning, trusted systems, optics and photonics, electromagnetics, plasma physics, radio frequency systems, and biomedical engineering. We move science from the laboratory to the field by building teams of recognized experts who deliver effective, high-value solutions and services to our customers. From public service to national security, we aspire to be a valued partner through our unwavering commitment to innovative and mission-focused solutions.
Advanced BioScience Laboratories, Inc (ABL) is a leading contract research and manufacturing organization, that partners with our clients to support their vaccine and therapeutic development programs. We offer a unique combination of preclinical and clinical services designed to first address the scientific challenges often encountered during proof-of-concept, and then streamline process development and cGMP production of clinical supply. ABL can assist with all aspects of production development including, but not limited to: Basic and translational research Vaccine and therapeutic product design Animal models for preclinical evaluation including immunomonitoring , efficacy and potency Cell line and process development cGMP manufacture of cell banks and virus banks cGMP manufacture of clinical supply for protein therapeutics, vaccines and live viral vectors Ask about our 9,000 sq ft clinical GCLP immunomonitoring space and our vaccine and therapeutic testing services. With a 50+ year history as a service provider to the life sciences industry, ABL brings a broad technical knowledge base, highly experienced work force, and seasoned project management to every program. Our goal is to become a seamless extension of our clients’ product development group – helping them advance today’s ideas into tomorrow’s medicines. Our history, capabilities and expertise allow ABL to provide solution based services to our clients.
Bioscan develops instrumentation for the detection, synthesis, and imaging of radio-labeled compounds used in several fields.
We're hiring! ZERO TO THREE is a national nonprofit organization that informs, trains and supports professionals, policymakers and parents in their efforts to improve the lives of infants and toddlers. Neuroscientists have documented that our earliest days, weeks and months of life are a period of unparalleled growth when trillions of brain cell connections are made. Research and clinical experience also demonstrate that health and development are directly influenced by the quality of care and experiences a child has with his parents and other adults. That is why at ZERO TO THREE our mission is to ensure all babies and toddlers have a strong start in life. We know that as babies, the way we are held, talked to and cared for teaches us about who we are and how we are valued. This profoundly shapes who we will become. Early experiences set a course for a lifelong process of discovery about ourselves and the world around us. Simply put, early experiences matter. We encourage you to learn more about very young children, early development and the work of ZERO TO THREE by exploring our site. Explore opportunities at zerotothree.org/careers
Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises. The Johns Hopkins Hospital opened in 1889, followed four years later by the university’s School of Medicine, revolutionizing medical practice, teaching, and research in the United States. The hospital is now part of the Johns Hopkins Health System, which includes two other acute-care hospitals and additional integrated health-care delivery components, with a network of primary and specialty care practices throughout Maryland, outpatient care, long-term care, and home care. The Johns Hopkins University opened in 1876 as America’s first research university, founded for the express purpose of expanding knowledge and putting that knowledge to work for the good of humanity. Two Interconnected Institutions: Over the years, the University and Hospital have grown, and—sometimes jointly, sometimes separately—they have created affiliated organizations. The Johns Hopkins Institutions is a collective name for the University and the Johns Hopkins Health System. The Johns Hopkins University includes nine academic and research divisions, and numerous centers, institutes, and affiliated entities. Johns Hopkins Medicine is a governing structure for the University’s School of Medicine and the health system, coordinating their research, teaching, patient care, and related enterprises.
At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
NuPulse is a medical device company developing novel technology to treat patients with heart failure.
Cerecor discovers, develops and commercializes neuroscience drugs.
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.
OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome-wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. Our flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collections and over 25,000 TrueORF cDNA clones. From our TrueORF cDNA clones, we have developed the largest offering of full-length human proteins expressed in mammalian cells, ideal for functional studies. In 2010, OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens to develop protein assays for every human protein. In addition, OriGene offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and validation OriGene is committed to its mission to be “Your Gene Company”, supplying everything a researcher needs for gene-based research. Visit us at https://www.origene.com
Work Your Passion. Live Your Purpose.
